Skip to main content
SpringerLink
Log in

Once-Weekly Fluoxetine

A Viewpoint by Alexander Neumeister and W. Wolfgang Fleischhacker

  • Adis New Formulation Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Keller MB. Long-term treatment of recurrent and chronic depression. J Clin Psychiatry 2001; 62 Suppl. 24: 3–5

    PubMed  Google Scholar 

  2. Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999; 56(12): 1109–15

    Article  PubMed  CAS  Google Scholar 

  3. Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996; 53(10): 924–32

    Article  PubMed  CAS  Google Scholar 

  4. Unutzer J, Rubenstein L, Katon WJ, et al. Two-year effects of quality improvement programs on medication management for depression. Arch Gen Psychiatry 2001; 58(10): 935–42

    Article  PubMed  CAS  Google Scholar 

  5. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Nov; 61(11): 851–7

    Article  PubMed  CAS  Google Scholar 

  6. Miner CM, Brown EB, Gonzales JS, et al. Switching patients from daily citalopram, paroxetine or sertraline to fluoxetine once-weekly in the maintenance of response for depression. 2001 Indianapolis (IN): Eli Lilly and Company. (Data on file)

    Google Scholar 

  7. Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Dec; 61(12): 928–32

    Article  PubMed  CAS  Google Scholar 

  8. Oehl M, Hummer M, Fleischhacker WW. Compliance with anti-psychotic treatment. Acta Psychiatr Scand Suppl 2000; 102(407): 83–6

    Article  Google Scholar 

  9. Reimherr FW, Strong RE, Marchant BK, et al. Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. J Clin Psychiatry 2001; 62 Suppl. 22: 16–23

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institutes of Health, NIMH, Mood and Anxiety Disorders Research Program, Bethesda, Maryland, USA

    Alexander Neumeister

  2. Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria

    W. Wolfgang Fleischhacker

Authors
  1. Alexander Neumeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Wolfgang Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neumeister, A., Fleischhacker, W.W. Once-Weekly Fluoxetine. Drugs 61, 2229–2230 (2001). https://doi.org/10.2165/00003495-200161150-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161150-00008

Search

Navigation